How to Predict Events in Order to Decide Whether to Revascularize Symptomatic Carotid Artery Stenosis

Current models are not reliable when it comes to predicting events after carotid revascularization in acute patients. Peri-procedural events seem to be particularly hard to predict. The development of models that can be externally validated is essential for the decision-making process in patients with high event rates, both during the procedure or while the case is “cooling off.”

Enfermedad carotidea asintomática: ¿Endarterectomía o angioplastia?That is why the aim of this work was to evaluate the short- and long-term external validity of previously published prediction models, which may have worked very well in the studies that featured them and (above all else) with the operators involved, but which may not be reproducible in a real-world setting with a patient with symptomatic severe carotid lesions.

 

For that purpose, researchers analyzed data on 2184 patients who underwent angioplasty and 2261 patients who underwent endarterectomy included in 4 randomized studies (EVA-3S, SPACE, ICSS, and CREST). Investigators assessed 23 models to estimate stroke or death within 30 days from the procedure and 7 models to predict long-term risk.


Read also: More Evidence For MitraClip in High Risk Patients with Severe Tricuspid Regurgitation.


Death or stroke occurred in 158 patients who underwent angioplasty (7.2%) and 84 patients who underwent endarterectomy (3.7%). Most models to predict short-term events after angioplasty (n = 4) or endarterectomy (n = 19) had very poor discriminative performance and poor calibration with small absolute risk differences between the lowest and highest risk patients and, in general, overestimation of risk in the highest risk patients.

 

As regards long-term outcome models, they had a slightly better performance and reasonable calibration. The problem is that we are dealing with acute patients: decisions must be made fast and what really tips the scales are peri-procedural events or events within 15 days, if a decision is made against revascularization.

 

Conclusion

None of the current models is reliable when it comes to making the decision to carry out a carotid revascularization in an acute patient. In particular, prediction of short-term outcomes, where the highest risk lies regardless of the decision made, seems to be a difficult task.

 

Original title: Prediction Models for Clinical Outcome After a Carotid Revascularization Procedure. An External Validation Study.

Reference: Eline J. Volkers et al. Stroke. 2018 Jul 16. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...